Dardonville Q, Salgueiro E, Rousseau V, Chebane L, Faillie JL, Gautier S, Montastruc JL, Carvajal A, Bagheri H. Drug-induced osteoporosis/osteomalacia: analysis in the French and Spanish pharmacovigilance databases. Eur J Clin Pharmacol 2019;75:1705-11. [Ref.ID 103213]

Taylor P. GSK’s says depot HIV injection works over three years. The injection could rival Gilead’s single-tablet therapy. PMLiVE 2018:30 de octubre. [Ref.ID 102836]

Anónimo. Rilpivirine et HIV chez les adolescents. Prescrire 2017;37:13-4. [Ref.ID 101362]

Anónimo. Elvitegravir (Vitekta) for HIV. Med Lett Drugs Ther 2016;58:10-1. [Ref.ID 100789]

Cervero M, Torres R, Jusdado JJ, Pastor S, Agud JL. Factores predictivos de las interacciones farmacológicas clínicamente significativas en los pacientes tratados con regímenes basados en los inhibidores de la proteasa, inhibidores de transcriptasa inversa no nucleósidos y raltegravir. Med Clin (Barc) 2016;146:339-45. [Ref.ID 100173]

Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister S, GS-US-292-0104/0111 Study Team. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015;385:2606-15. [Ref.ID 99315]

Anónimo. Éfavirenz: suicides. Prescrire 2015;35:105. [Ref.ID 98917]

Anónimo. Triumeq: a 3-drug combination for HIV. Med Lett Drugs Ther 2015;57:7-8. [Ref.ID 98699]

Raffi F, Babiker AG, Richert L, Molina J-M, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy J-F, Vella S, Chêne G, Pozniak A, for the NEAT001/ANRS143 Study Group. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet 2014;384:1942-51. [Ref.ID 98452]

Anónimo. Etravirine et HIV chez les enfants de plus de 6 ans. Prescrire 2014;34:416. [Ref.ID 97946]

Anónimo. Dolutégravir. Prescrire 2014;34:414-5. [Ref.ID 97945]

Anónimo. Raltégravir et HIV chez les enfants de plus de 2 ans. Prescrire 2014;34:413. [Ref.ID 97944]

Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbel TB, Sax PE, Gulick RM, O'Keefe L, Robertson KR, Tierney C. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med 2014;161:1-10. [Ref.ID 97795]

Pozniak AL, Arribas JR. FLAMINGO: how much rosier can antiretroviral therapy get?. Lancet 2014;383:2191-3. [Ref.ID 97736]

Clotet B, Feinberg J, van Lunzen J, Khuong-Josses M, Antinori A, Dumitru I, Pokrovskiy V, Fehr J, Ortiz R, Saag M, Harris J, Brennan C, Fujiwara T, Min S, on behalf of the ING114915 Study Team. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 2014;383:2222-31. [Ref.ID 97734]

Anónimo. Elvitegravir/cobicistat/emtricitabina/tenofovir. Stribild (Gilead). Infección por VIH. PAM 2014;38:39-48. [Ref.ID 97722]

Anónimo. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2014. A clinical practice guidelines. Centers for Disease Control and Prevention 2014:16 de mayo. [Ref.ID 97586]

Anónimo. Atteintes des ongles d'origine médicamenteuse. Prescrire 2014;34:191-4. [Ref.ID 97362]

Anónimo. Drug-induced liver injury. Australian Prescriber 2013;36:168-9. [Ref.ID 96320]

Anónimo. Cobicistat + elvitégravir + emtricitabine + ténofovir. Prescrire 2013;33:408-11. [Ref.ID 95570]